A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Thomas Jefferson University
Ohio State University Comprehensive Cancer Center
Yale University
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Prescient Therapeutics, Ltd.
Abramson Cancer Center at Penn Medicine
Chengdu Zenitar Biomedical Technology Co., Ltd
M.D. Anderson Cancer Center
University of Michigan Rogel Cancer Center
Columbia University
Institute of Hematology & Blood Diseases Hospital, China
City of Hope Medical Center
Columbia University
Ohio State University Comprehensive Cancer Center
City of Hope Medical Center
Yale University
Ohio State University Comprehensive Cancer Center
University College, London
Innate Pharma
BeiGene
4SC AG
Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd.
Northwestern University
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
University of Nebraska
University of Nebraska
Genmab
OncoSec Medical Incorporated
Stanford University
Genmab
Universitätsmedizin Mannheim
Karyopharm Therapeutics Inc
miRagen Therapeutics, Inc.
Cyclacel Pharmaceuticals, Inc.
Rochester Skin Lymphoma Medical Group, PLLC
European Organisation for Research and Treatment of Cancer - EORTC
Novartis
Novartis
Eisai Inc.
Rochester General Hospital
Galderma R&D
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
miRagen Therapeutics, Inc.
National Cancer Institute (NCI)
Eli Lilly and Company